- Home
- MTVA vs IMNN Comparison
MTVA vs IMNN Comparison
Compare MTVA & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTVA
- IMNN
- Stock Information
- Founded
- MTVA 2014
- IMNN 1982
- Country
- MTVA United States
- IMNN United States
- Employees
- MTVA N/A
- IMNN N/A
- Industry
- MTVA
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- MTVA
- IMNN Health Care
- Exchange
- MTVA NYSE
- IMNN Nasdaq
- Market Cap
- MTVA 14.3M
- IMNN 12.1M
- IPO Year
- MTVA N/A
- IMNN 1985
- Fundamental
- Price
- MTVA $0.71
- IMNN $7.00
- Analyst Decision
- MTVA Strong Buy
- IMNN Buy
- Analyst Count
- MTVA 2
- IMNN 2
- Target Price
- MTVA $7.50
- IMNN $210.00
- AVG Volume (30 Days)
- MTVA 64.8K
- IMNN 285.4K
- Earning Date
- MTVA 08-13-2025
- IMNN 08-13-2025
- Dividend Yield
- MTVA N/A
- IMNN N/A
- EPS Growth
- MTVA N/A
- IMNN N/A
- EPS
- MTVA N/A
- IMNN N/A
- Revenue
- MTVA N/A
- IMNN N/A
- Revenue This Year
- MTVA N/A
- IMNN N/A
- Revenue Next Year
- MTVA N/A
- IMNN N/A
- P/E Ratio
- MTVA N/A
- IMNN N/A
- Revenue Growth
- MTVA N/A
- IMNN N/A
- 52 Week Low
- MTVA $0.60
- IMNN $5.55
- 52 Week High
- MTVA $4.36
- IMNN $54.75
- Technical
- Relative Strength Index (RSI)
- MTVA N/A
- IMNN 35.49
- Support Level
- MTVA N/A
- IMNN $7.46
- Resistance Level
- MTVA N/A
- IMNN $9.35
- Average True Range (ATR)
- MTVA 0.00
- IMNN 1.23
- MACD
- MTVA 0.00
- IMNN 0.08
- Stochastic Oscillator
- MTVA 0.00
- IMNN 9.00
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).